Holen Sie sich die Stockscreener-App
4.58
2.45%
-0.11
Handel nachbörslich:
4.65
0.07
+1.53%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ACHV?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.69
Offen:
$4.6
24-Stunden-Volumen:
990.55K
Relative Volume:
0.86
Marktkapitalisierung:
$468.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.65M
KGV:
-3.5372
EPS:
-1.2948
Netto-Cashflow:
$-49.47M
1W Leistung:
+2.81%
1M Leistung:
+13.81%
6M Leistung:
-5.48%
1J Leistung:
+50.49%
1-Tages-Spanne:
$4.55
$4.74
1-Wochen-Bereich:
$4.44
$4.81
52-Wochen-Spanne:
$2.00
$6.15
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Firmenname
Achieve Life Sciences Inc
Sektor
Branche
Telefon
425-686-1500
Adresse
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.565 | 481.47M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-11-25 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-08-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Strong Buy |
| 2023-05-10 | Bestätigt | Maxim Group | Buy |
| 2021-06-23 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Achieve Life Sciences Inc Aktie (ACHV) Neueste Nachrichten
Achieve Life Sciences 4Q Loss/Shr 28c >ACHV - Moomoo
[EFFECT] ACHIEVE LIFE SCIENCES, INC. SEC Filing - Stock Titan
Canaccord reiterates Achieve Life Sciences stock rating on safety data By Investing.com - Investing.com South Africa
Achieve Life Sciences (ACHV) price target decreased by 14.04% to 12.82 - MSN
Canaccord reiterates Achieve Life Sciences stock rating on safety data - Investing.com
Q3 2025 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
ACHV Should I Buy - Intellectia AI
ACHV Technical Analysis | Trend, Signals & Chart Patterns | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences presents long-term cytisinicline data - Investing.com UK
Achieve Life Sciences presents long-term cytisinicline data By Investing.com - Investing.com Nigeria
Achieve Life Sciences, Inc.: cytisinicline data indicate well-tolerated safety over 52 weeks for adults quitting smoking - Traders Union
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline in Smoking Cessation at ATS 2026 - Quiver Quantitative
Year-long test of quit-smoking pill cytisinicline finds low nausea - Stock Titan
Achieve Life Sciences Q1 earnings call highlights - MSN
Achieve (ACHV) Q1 2026 Earnings Transcript - AOL.com
Q2 Earnings Forecast for ACHV Issued By Zacks Research - MarketBeat
Canaccord Genuity initiates coverage of Achieve Life Sciences (ACHV) with buy recommendation - MSN
Earnings call transcript: Achieve Life Sciences beats Q1 2026 EPS expectations - Investing.com
HC Wainwright Has Optimistic Outlook of ACHV Q2 Earnings - MarketBeat
[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan
Director at ACHIEVE Life Sciences (ACHV) granted 47,250 stock options at $5.59 - Stock Titan
Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission - Seeking Alpha
Achieve Life Sciences, Inc.Common Shares (NQ: ACHV - FinancialContent
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2026 Earnings Call Transcript - Insider Monkey
Achieve Life Sciences (ACHV) registers 99.04M shares for resale by investors - Stock Titan
Achieve Life Sciences Releases Q1 2026 Financial Results - AlphaStreet
Achieve Life Sciences (ACHV) Secures $180M Financing for Cytisin - GuruFocus
Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Achieve Life Sciences Q1 2026 beats EPS expectations - Investing.com
Achieve Life Sciences Q1 2026: Loss Narrows 38.7% to -$0.19/Share - AlphaStreet
Achieve Life Sciences Q1 Earnings Call Highlights - MarketBeat
Achieve Life Sciences adds three executives to leadership team By Investing.com - Investing.com South Africa
ACHV: Achieve Aims for FDA Approval of Cytisinicline as New Smok - GuruFocus
How Should Investors Value Achieve Life Sciences (ACHV) After Q1 - GuruFocus
Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Achieve Life Sciences Closes $354M Financing, Advances Cytisinicline for Smoking & Vaping Cessation with FDA Review in 2026 - Minichart
Achieve Life Sciences Q1 loss narrows more than expected - TradingView
Q1 2026 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
ACHV Stock Surges After Achieve Life Sciences Reports Market-Beating Q1 2026 Earnings - ChartMill
Achieve Life Sciences Adds Director Amid Board Transitions - TipRanks
Achieve Life Sciences adds three executives to leadership team - Investing.com
ACHIEVE LIFE SCIENCES ($ACHV) Releases Q1 2026 Earnings - Quiver Quantitative
Achieve Life Sciences (NASDAQ: ACHV) posts Q1 loss, funds cytisinicline with $180M raise - Stock Titan
Finanzdaten der Achieve Life Sciences Inc-Aktie (ACHV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Achieve Life Sciences Inc-Aktie (ACHV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):